Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Lactobacillus rhamnosus HN001 and Reduced Eczema Risk

Doses used in studies

CFU single-dose: 6 billion (median 6 billion, IQR 6 billion–6 billion) — 1 study

Time to effect

Median: 24.3 months · IQR 24.3 months–24.3 months · Range 24.3 months–24.3 months — Reported in 1 of 1 study

1 of 1 paper

Eczema-protective probiotic alters infant gut microbiome functional capacity but not composition: sub-sample analysis from a RCT.
- 2019-02-08
- RCT · n = 474
- Beneficial microbes 10(1)
- - R Murphy
  - X C Morgan
  - X Y Wang
  - K Wickens
  - G Purdie
  - P Fitzharris
  - A Otal
  - B Lawley
  - T Stanley
  - C Barthow
  - J Crane
  - E A Mitchell
  - G W Tannock
- PubMed: 30574802
- DOI: 10.3920/bm2017.0191
1 Insight on
- Reduced Eczema Risk
- High evidence
- Large Human Trial
- Rigorous Journal
- Infants
There was a 50% reduced eczema risk in the HN001 probiotic group compared to placebo.
Effect
Neutral
Effect size
Small
Significant
No
Dose
9×10^9 cfu